Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | CTSA | P10619 | 8/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514812 | 0.81 | ALOX5 (0.41) | ALOX5CTSAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL6011470 | 0.81 | FFAR2 (0.46) | ALOX5CTSASMN1; SMN2LMNASLC6A3 | |
| SCHEMBL12064962 | 0.81 | CTSA (0.45) | ALOX5CTSAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL31090349 | 0.81 | ALOX5 (0.41) | ALOX5CTSASMN1; SMN2LMNAKDM4E | |
| SCHEMBL17064896 | 0.81 | ALOX5 (0.53) | ALOX5CTSA | |
| SCHEMBL4768669 | 0.81 | ALDH1A1 (0.42) | ALOX5CTSAPDPK1LMNAKDM4E | |
| SCHEMBL7901954 | 0.80 | CTSA (0.48) | CTSAPDPK1LMNAGRM5SLC6A3 | |
| SCHEMBL4030982 | 0.79 | ALOX5 (0.40) | ALOX5CTSAKDM4ENPC1RAB9A | |
| SCHEMBL2593428 | 0.77 | CTSA (0.46) | ALOX5CTSAPDPK1LMNAGRM5 | |
| SCHEMBL11172666 | 0.77 | KMT2A (0.47) | CTSAPDPK1LMNASLC6A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | claimed |
| EP-4117647-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | Purdue Research Foundation (US) | 2023-01-18 | — | — | EP | claimed |
| CN-115551497-A | Compounds with immunomodulatory activity and therapeutic uses thereof | 普渡研究基金会 | 2022-12-30 | — | — | CN | claimed |
| WO-2021183370-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2021-09-16 | — | — | WO | claimed |
| US-12448359-B2 | Compounds with immunomodulatory activity and therapeutic uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-10-21 | — | — | US | disclosed |
| CN-115551497-B | Compounds with immunomodulatory activity and therapeutic uses thereof | 普渡研究基金会 | 2024-11-08 | — | — | CN | disclosed |
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4117647-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | Purdue Research Foundation (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115551497-A | Compounds with immunomodulatory activity and therapeutic uses thereof | 普渡研究基金会 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021183370-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2021-09-16 | — | — | WO | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-0861843-A2 | Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5672567-A | PRE- AND POST-EMERGENCE | ZENECA LIMITED (GB) | 1997-09-30 | — | — | US | disclosed |
| US-5670453-A | PYRAZINEARYL COMPOUND | ZENECA LIMITED (GB) | 1997-09-23 | — | — | US | disclosed |
| EP-0758323-A1 | HERBICIDAL HYDROXYBENZYL-SUBSTITUTED HETEROARYL COMPOUNDS AND DERIVATIVES THEREOF | ZENECA LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5474743-A | A fluorescent ionophoric compound comprising a cryptand portion and a coumarin portion substituted at the 3-position with an electron withdrawing group | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995029898-A1 | HERBICIDAL HYDROXYBENZYL-SUBSTITUTED HETEROARYL COMPOUNDS AND DERIVATIVES THEREOF | ZENECA LIMITED (GB) | 1995-11-09 | — | — | WO | disclosed |
| CN-1106407-A | Cation-sensitive composite structures and compounds for use therein | MINNESOTA MINING & MFG (US) | 1995-08-09 | — | — | CN | disclosed |
| EP-0649848-A1 | Cation-sensing composite structure and compounds for use therein | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | CD47, CD74, ICOS | ALOX5 268/4885CTSA 275/4885HPGD 850/4885 |
| US-12448359-B2 | Compounds with immunomodulatory activity and therapeutic uses thereof | CD47, CD74, ICOS | ALOX5 268/4885CTSA 275/4885HPGD 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.